News
Aromatase inhibitor cuts risk of recurrence of breast cancer
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7440.599-a (Published 11 March 2004) Cite this as: BMJ 2004;328:599- Caroline White
- London
Switching postmenopausal women with breast cancer to the aromatase inhibitor exemestane after two to three years of treatment with tamoxifen keeps them free of disease for longer than treating them with tamoxifen alone, suggests an interim analysis of trial data. After a median of 30 months follow up, it made little difference to survival, however.
The authors conclude that standard adjuvant treatment with five years of tamoxifen may no …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.